For decades, the scientific community has sought to harness the formidable power of the human immune system to combat cancer, a strategy known as immunotherapy. While significant strides have been made, particularly with checkpoint inhibitors, many patients still do not respond, and existing treatments can carry substantial side effects. A particularly intriguing class of compounds, CD40 agonist antibodies, emerged over two decades ago with considerable promise due to their ability to activate key components of the immune response. However, early clinical investigations into these agents often yielded disappointing outcomes, characterized by only marginal therapeutic benefits coupled with a high incidence of severe systemic toxicities such as widespread inflammation, dangerously low platelet counts, and liver damage, even at relatively conservative dosages. This presented a significant hurdle, as the therapeutic window—the balance between efficacy and safety—proved too narrow for widespread clinical adoption.
CD40 is a pivotal receptor belonging to the tumor necrosis factor (TNF) receptor superfamily, predominantly expressed on immune cells like antigen-presenting cells (APCs) such as dendritic cells and B cells. Its activation plays a critical role in orchestrating robust anti-tumor immunity by enhancing antigen presentation, promoting the maturation of dendritic cells, and facilitating the co-stimulation required for effective T-cell activation and proliferation. Traditional CD40 agonists aimed to broadly stimulate this pathway, but their systemic administration meant that CD40 receptors throughout the body, including on healthy tissues, were engaged. This indiscriminate activation led to the unacceptable systemic inflammation and other adverse events that plagued earlier trials. The challenge for researchers became how to retain the potent immune-activating properties of CD40 agonism while mitigating its widespread collateral damage.
A pivotal shift in strategy emerged from the Rockefeller University, where a team led by Dr. Jeffrey V. Ravetch embarked on an innovative redesign of the CD40 agonist antibody. Their work, initially reported in 2018, focused on engineering a variant that could overcome the limitations of its predecessors. With critical support from Rockefeller’s Therapeutic Development Fund, established by trustee Julian Robertson and sustained by the Black Family Foundation, the researchers meticulously modified the antibody, now designated 2141-V11. This redesigned molecule was engineered to bind with high affinity to human CD40 receptors and, crucially, was enhanced to improve its "crosslinking" capabilities by interacting specifically with a particular Fc receptor. This Fc-mediated crosslinking is essential for robust signaling through the CD40 receptor, effectively amplifying the immune signal. Laboratory studies, employing specially engineered mouse models that closely recapitulate human immune pathways, demonstrated that this novel design was approximately ten times more potent at initiating an immune attack against tumor cells compared to earlier versions.
Beyond the molecular engineering, the Rockefeller team introduced a radical change in the delivery methodology. Prior CD40 therapies were typically administered via intravenous infusion, leading to systemic exposure and the aforementioned toxicities. Recognizing that the goal was to stimulate anti-tumor immunity locally, within the tumor microenvironment, the researchers opted for direct intratumoral injection. This approach, akin to an "in situ vaccination," aims to concentrate the immune-stimulating effects directly where the cancer resides, thereby minimizing the systemic distribution of the drug and its potential side effects. The preclinical findings were highly encouraging, suggesting that this localized delivery strategy could unlock the therapeutic potential of CD40 agonism while dramatically improving its safety profile. Indeed, initial observations from this refined delivery method indicated only mild, localized toxicity.
These promising preclinical results paved the way for a Phase 1 clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of 2141-V11 in human patients. The findings from this crucial early-stage study have now been published in the journal Cancer Cell, offering a compelling glimpse into the potential of this novel approach. The trial enrolled 12 participants grappling with various advanced metastatic cancers, including melanoma, renal cell carcinoma, and different forms of breast cancer—diseases known for their aggressive nature and challenging treatment landscapes. Remarkably, none of the participants experienced the severe, dose-limiting systemic toxicities that had historically plagued earlier CD40 agonist trials. This dramatic improvement in the safety profile represented a monumental achievement in itself, addressing one of the primary roadblocks to this class of drugs.
Beyond safety, the efficacy signals were profoundly encouraging for an early-phase trial. Tumors shrank in six of the twelve patients, indicating a significant anti-cancer effect. More strikingly, two of these patients achieved a complete remission, meaning all detectable signs of their cancer vanished entirely. Dr. Juan Osorio, the first author on the study, a visiting assistant professor in Dr. Ravetch’s Leonard Wagner Laboratory of Molecular Genetics and Immunology, and a medical oncologist at Memorial Sloan Kettering Cancer Center, expressed his astonishment: "To observe such significant tumor shrinkage and even complete remission in a cohort of this size is truly extraordinary."
Perhaps the most groundbreaking and unexpected observation from the trial was the demonstration of a systemic anti-tumor response originating from a localized treatment. The therapy did not merely impact the specific tumor injected; distant, uninjected tumors located elsewhere in the body also exhibited significant shrinkage or complete elimination by the activated immune cells. Dr. Ravetch underscored the rarity and significance of this phenomenon: "This effect, where a local injection triggers a systemic response throughout the body, is not a common occurrence in clinical oncology. It stands out as another highly dramatic and unanticipated outcome from our study." This "abscopal effect," a term used to describe the regression of untreated metastatic tumors following localized treatment of a primary tumor, is a highly sought-after outcome in cancer immunotherapy, as it holds the potential to treat widespread metastatic disease with a targeted intervention.
The two patients who experienced complete remission provided compelling real-world examples of this systemic effect. One patient, battling aggressive melanoma, presented with dozens of metastatic lesions across her leg and foot. The researchers selectively injected just a single tumor located on her thigh. Following multiple injections into this solitary site, all other metastatic tumors throughout her body completely regressed. A similar astonishing outcome was observed in a patient diagnosed with metastatic breast cancer, who had tumors in her skin, liver, and lung. Despite only injecting the cutaneous lesion, all her other visceral metastases disappeared. These cases vividly illustrate the potential for a locally administered therapy to generate a broad, body-wide anti-cancer immune response.
To unravel the underlying mechanisms behind these remarkable clinical observations, researchers meticulously analyzed samples from the treated tumors. These analyses revealed a profound transformation within the tumor microenvironment. Post-treatment, the injected tumors became densely infiltrated with a diverse array of immune cells, including various types of dendritic cells, T cells, and mature B cells. These immune cells aggregated into organized structures remarkably akin to lymph nodes, known as tertiary lymphoid structures (TLS). Dr. Osorio elaborated on this critical finding: "The drug effectively reshapes the immune microenvironment within the tumor, essentially replacing cancerous tissue with these highly organized tertiary lymphoid structures."
Tertiary lymphoid structures are recognized as critical hubs for the initiation and sustenance of anti-tumor immunity. Their presence within tumors is frequently correlated with improved patient prognoses and a more robust response to various forms of immunotherapy. These structures serve as local sites for antigen presentation, T-cell priming, and the ongoing education of the immune system to recognize and eliminate cancer cells. Crucially, the researchers also detected the formation of TLS in distant, non-injected tumors, providing a tangible link to the observed abscopal effect. As Dr. Osorio explained, "Once the immune system is primed to identify the cancer cells within the injected tumor, these activated immune cells subsequently migrate to the non-injected tumor sites, propagating the anti-tumor response throughout the body." This suggests that the injected tumor acts as a potent immunological training ground, disseminating antigen-specific effector cells capable of eradicating distant metastases.
Encouraged by these highly promising initial results, Dr. Ravetch’s group has expanded its research efforts, initiating additional clinical trials in collaboration with scientists at Memorial Sloan Kettering Cancer Center and Duke University. Current Phase 1 and Phase 2 studies are actively evaluating 2141-V11 across a broader spectrum of notoriously difficult-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma, a highly aggressive brain tumor. These expanded trials collectively involve nearly 200 patients, aiming to gather more extensive data on safety, efficacy, and the nuanced mechanisms of response.
A primary objective of these larger studies is to elucidate why certain patients respond profoundly to the treatment while others do not, and to identify strategies to enhance response rates across a wider patient population. Early insights from the initial trial have already provided clues: both patients who achieved complete remission exhibited high clonality of T cells at the commencement of the study. T-cell clonality refers to the diversity and expansion of specific T-cell populations, indicating a pre-existing or readily activatable antigen-specific immune response. Dr. Ravetch noted, "This observation suggests that certain pre-existing characteristics of a patient’s immune system may be prerequisites for the optimal function of this drug. We are currently dissecting these immunological features in greater detail within these larger ongoing studies."
Understanding these predictive factors is paramount for the advancement of personalized cancer medicine. As a general rule, only a fraction of patients—typically between 25% and 30%—respond to conventional immunotherapies. This presents a significant challenge for the field. "The greatest hurdle in immunotherapy remains identifying which patients will benefit from a given treatment," Dr. Ravetch emphasized. "We need to pinpoint reliable indicators or biomarkers of response. Furthermore, a crucial goal is to develop strategies that can convert non-responders into responders, thereby broadening the impact of these life-saving therapies." The ongoing research into 2141-V11 exemplifies the dynamic interplay between innovative drug design, targeted delivery, and meticulous immunological investigation, offering a new beacon of hope in the continuous fight against cancer.
About the Author
